The role of "watch and wait" in intestinal follicular lymphoma in rituximab era

Akira Tari, Hideki Asaoku, Katsuyoshi Takata, Shunji Fujimori, Shinji Tanaka, Megumu Fujihara, Tadashi Koga, Tadashi Yoshino

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: There is no consensus regarding the best treatment for intestinal follicular lymphoma (FL). We used "watch and wait" for patients with intestinal FL with low-tumor-burden (LTB) criteria and without mass formation causing bowel obstruction. We investigated the overall survival (OS) and time to treatment required (TTR). Methods: Thirty-three intestinal FL patients [clinical stage (CS) I:16, II1:0, II2:7, IV:10; median observation period: 45.5 months, range: 13-110 months] were diagnosed via endoscopy. Detailed clinical and pathological examinations were performed, and neoplastic process behavior was monitored. Results: All of the 33 patients were WHO grade 1. FL lesions in the digestive tract were found frequently in the second-fourth portion of the duodenum in 91% of the patients; 87% of those patients had lesions in a broader area including the small intestine. Two patients had an enlargement of the area of the lesions and a worsening of the macroscopic findings. Three patients had CS progression; however, these remained within the indication for "watch and wait." Two patients with transformation into diffuse large B-cell lymphoma received rituximab and chemotherapy, which led to complete remission. The OS was 100%. The time to treatment required (TTR) was 49 months in one patient and 37 months in one patient. Conclusion: Intestinal FL in CS I-IV with broad infiltration of the digestive tract meeting the criteria for LTB had a remarkably slow course. This study suggests that "watch and wait" is appropriate for the treatment of LTB intestinal FL even in the era of rituximab.

Original languageEnglish
Pages (from-to)321-328
Number of pages8
JournalScandinavian Journal of Gastroenterology
Volume51
Issue number3
DOIs
Publication statusPublished - Mar 3 2016

Fingerprint

Follicular Lymphoma
Tumor Burden
Gastrointestinal Tract
Rituximab
Neoplastic Processes
Survival
Lymphoma, Large B-Cell, Diffuse
Therapeutics
Duodenum
Endoscopy
Small Intestine
Observation
Drug Therapy

Keywords

  • Histologic transformation
  • Intestinal follicular lymphoma
  • Low-tumor-burden
  • Treatment
  • Watch and wait

ASJC Scopus subject areas

  • Gastroenterology

Cite this

The role of "watch and wait" in intestinal follicular lymphoma in rituximab era. / Tari, Akira; Asaoku, Hideki; Takata, Katsuyoshi; Fujimori, Shunji; Tanaka, Shinji; Fujihara, Megumu; Koga, Tadashi; Yoshino, Tadashi.

In: Scandinavian Journal of Gastroenterology, Vol. 51, No. 3, 03.03.2016, p. 321-328.

Research output: Contribution to journalArticle

Tari, Akira ; Asaoku, Hideki ; Takata, Katsuyoshi ; Fujimori, Shunji ; Tanaka, Shinji ; Fujihara, Megumu ; Koga, Tadashi ; Yoshino, Tadashi. / The role of "watch and wait" in intestinal follicular lymphoma in rituximab era. In: Scandinavian Journal of Gastroenterology. 2016 ; Vol. 51, No. 3. pp. 321-328.
@article{da45a80953ed4d708d3095f4cb104ea4,
title = "The role of {"}watch and wait{"} in intestinal follicular lymphoma in rituximab era",
abstract = "Objective: There is no consensus regarding the best treatment for intestinal follicular lymphoma (FL). We used {"}watch and wait{"} for patients with intestinal FL with low-tumor-burden (LTB) criteria and without mass formation causing bowel obstruction. We investigated the overall survival (OS) and time to treatment required (TTR). Methods: Thirty-three intestinal FL patients [clinical stage (CS) I:16, II1:0, II2:7, IV:10; median observation period: 45.5 months, range: 13-110 months] were diagnosed via endoscopy. Detailed clinical and pathological examinations were performed, and neoplastic process behavior was monitored. Results: All of the 33 patients were WHO grade 1. FL lesions in the digestive tract were found frequently in the second-fourth portion of the duodenum in 91{\%} of the patients; 87{\%} of those patients had lesions in a broader area including the small intestine. Two patients had an enlargement of the area of the lesions and a worsening of the macroscopic findings. Three patients had CS progression; however, these remained within the indication for {"}watch and wait.{"} Two patients with transformation into diffuse large B-cell lymphoma received rituximab and chemotherapy, which led to complete remission. The OS was 100{\%}. The time to treatment required (TTR) was 49 months in one patient and 37 months in one patient. Conclusion: Intestinal FL in CS I-IV with broad infiltration of the digestive tract meeting the criteria for LTB had a remarkably slow course. This study suggests that {"}watch and wait{"} is appropriate for the treatment of LTB intestinal FL even in the era of rituximab.",
keywords = "Histologic transformation, Intestinal follicular lymphoma, Low-tumor-burden, Treatment, Watch and wait",
author = "Akira Tari and Hideki Asaoku and Katsuyoshi Takata and Shunji Fujimori and Shinji Tanaka and Megumu Fujihara and Tadashi Koga and Tadashi Yoshino",
year = "2016",
month = "3",
day = "3",
doi = "10.3109/00365521.2015.1087589",
language = "English",
volume = "51",
pages = "321--328",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The role of "watch and wait" in intestinal follicular lymphoma in rituximab era

AU - Tari, Akira

AU - Asaoku, Hideki

AU - Takata, Katsuyoshi

AU - Fujimori, Shunji

AU - Tanaka, Shinji

AU - Fujihara, Megumu

AU - Koga, Tadashi

AU - Yoshino, Tadashi

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Objective: There is no consensus regarding the best treatment for intestinal follicular lymphoma (FL). We used "watch and wait" for patients with intestinal FL with low-tumor-burden (LTB) criteria and without mass formation causing bowel obstruction. We investigated the overall survival (OS) and time to treatment required (TTR). Methods: Thirty-three intestinal FL patients [clinical stage (CS) I:16, II1:0, II2:7, IV:10; median observation period: 45.5 months, range: 13-110 months] were diagnosed via endoscopy. Detailed clinical and pathological examinations were performed, and neoplastic process behavior was monitored. Results: All of the 33 patients were WHO grade 1. FL lesions in the digestive tract were found frequently in the second-fourth portion of the duodenum in 91% of the patients; 87% of those patients had lesions in a broader area including the small intestine. Two patients had an enlargement of the area of the lesions and a worsening of the macroscopic findings. Three patients had CS progression; however, these remained within the indication for "watch and wait." Two patients with transformation into diffuse large B-cell lymphoma received rituximab and chemotherapy, which led to complete remission. The OS was 100%. The time to treatment required (TTR) was 49 months in one patient and 37 months in one patient. Conclusion: Intestinal FL in CS I-IV with broad infiltration of the digestive tract meeting the criteria for LTB had a remarkably slow course. This study suggests that "watch and wait" is appropriate for the treatment of LTB intestinal FL even in the era of rituximab.

AB - Objective: There is no consensus regarding the best treatment for intestinal follicular lymphoma (FL). We used "watch and wait" for patients with intestinal FL with low-tumor-burden (LTB) criteria and without mass formation causing bowel obstruction. We investigated the overall survival (OS) and time to treatment required (TTR). Methods: Thirty-three intestinal FL patients [clinical stage (CS) I:16, II1:0, II2:7, IV:10; median observation period: 45.5 months, range: 13-110 months] were diagnosed via endoscopy. Detailed clinical and pathological examinations were performed, and neoplastic process behavior was monitored. Results: All of the 33 patients were WHO grade 1. FL lesions in the digestive tract were found frequently in the second-fourth portion of the duodenum in 91% of the patients; 87% of those patients had lesions in a broader area including the small intestine. Two patients had an enlargement of the area of the lesions and a worsening of the macroscopic findings. Three patients had CS progression; however, these remained within the indication for "watch and wait." Two patients with transformation into diffuse large B-cell lymphoma received rituximab and chemotherapy, which led to complete remission. The OS was 100%. The time to treatment required (TTR) was 49 months in one patient and 37 months in one patient. Conclusion: Intestinal FL in CS I-IV with broad infiltration of the digestive tract meeting the criteria for LTB had a remarkably slow course. This study suggests that "watch and wait" is appropriate for the treatment of LTB intestinal FL even in the era of rituximab.

KW - Histologic transformation

KW - Intestinal follicular lymphoma

KW - Low-tumor-burden

KW - Treatment

KW - Watch and wait

UR - http://www.scopus.com/inward/record.url?scp=84947045052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947045052&partnerID=8YFLogxK

U2 - 10.3109/00365521.2015.1087589

DO - 10.3109/00365521.2015.1087589

M3 - Article

VL - 51

SP - 321

EP - 328

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 3

ER -